Navigation Links
Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
Date:2/4/2009

SAN DIEGO, Feb. 4 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at the 11th Annual BIO CEO & Investor Conference. The details are as follows:

    Corporate Presentation:
    Date:  Monday, February 9, 2009
    Time:  3:45 p.m. - 4:15 p.m. Eastern
    Location: Waldorf Astoria, Astor Room, New York
    Speaker: Graham Cooper, Chief Financial Officer

    Panel Discussion:
    Feeding the Need for New Treatments in Obesity
    Date:  Monday, February 9, 2009
    Time:  11:00 a.m. - 12:10 p.m. Eastern
    Location: Waldorf Astoria, East Foyer, New York
    Speaker: Dr. Dennis Kim, Senior Vice President, Corporate Development

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates are Contrave, which is in Phase 3 clinical trials, and Empatic, which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the company can be found at http://www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
2. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
3. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
4. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
5. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
6. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
7. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
8. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
9. Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement
10. Omnitura Therapeutics Announces Private Placement Financing
11. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... San Francisco, CA (PRWEB) , ... August 22, ... ... epidemic risk modeling, announced that two market innovators, Munich Re , one ... In-Q-Tel, Inc. (IQT), the strategic investor that accelerates the development of technologies ...
(Date:8/23/2017)... ... August 23, 2017 , ... Heidelberg Instruments ... advanced VPG+ 800 Volume Pattern Generators from two major Asian based phtotomask production ... production of advanced photomasks as well as a solution for mid volume direct ...
(Date:8/22/2017)... NC (PRWEB) , ... August 22, 2017 , ... ... company focused on the development and distribution of highly differentiated spinal implant technologies, ... Luke Maher brings 15 years of spinal device industry experience to directing ...
(Date:8/21/2017)... ... August 20, 2017 , ... Brian Pogue ... starting 1 January 2018. The journal is published by SPIE, the international society ... the use of modern optical technology for improved health care and biomedical research. ...
Breaking Biology Technology:
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/4/2017)... 2017   EyeLock LLC , a leader of ... States Patent and Trademark Office (USPTO) has issued U.S. ... of an iris image with a face image acquired ... company,s 45 th issued patent. ... given the multi-modal biometric capabilities that have recently come ...
Breaking Biology News(10 mins):